Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Right-of-use Assets

Note 5 - Right-of-use Assets

9 Months Ended

Sep. 30, 2023

Notes to Financial Statements

Right-of-use assets

5.

Right-of-use assets:


		September 30,				December 31,
		2023				2022
Right-of-use assets, beginning of period		$	3,100			$	1,860
Additions to right-of-use assets			24				1,240
Right-of-use assets, end of period			3,124				3,100
Accumulated amortization			(2,089	)			(1,803	)
Right-of use assets, NBV		$	1,035			$	1,297